Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Merger consummated July 13, 2026, triggering Nasdaq delisting proceedings.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.03 · Creation of a Direct Financial Obligation
- Merger consummated July 13, 2026, triggering Nasdaq delisting proceedings
- Nasdaq Form 25 requested to remove Common Stock from exchange listing and deregister under Section 12(b)
- Form 15 planned to suspend SEC reporting obligations under Sections 13 and 15(d)
- Shareholders lose Nasdaq trading and ongoing public-company reporting protections
Item 5.01 · Changes in Control of Registrant
- Esperion became a wholly owned subsidiary of Parent upon merger completion
- Change of control removes Esperion as an independently controlled public company
- Merger terms and ownership implications require review of the Introductory Note and related exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Six pre-merger directors ceased serving at the merger’s effective time
- Justin Bateman and Ankit Pareek elected as company directors
- Board turnover reflects merger control transition and potential shift in strategic oversight
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Third Amended and Restated Certificate of Incorporation and Bylaws became effective July 13, 2026
- Amendments align Esperion’s governing documents with the Essence merger transaction
- Second Supplemental Indenture adds Essence Parent Inc. to Esperion’s debt framework
- Contingent Value Rights Agreement creates shareholder rights tied to specified future transaction outcomes
- Investor focus: merger-related changes may affect governance, debt obligations, and potential shareholder consideration
Other items in this filing:
- Item 2.01: Completion of Acquisition or Disposition of Assets
- Item 1.01: Entry into a Material Definitive Agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.